An interventional study of Defibrillation using the Extravascular ICD in Tachycardia and Ventricular Arrythmia, sponsored by Medtronic Cardiac Rhythm and Heart Failure. Completed at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-03.
Sponsored by Medtronic Cardiac Rhythm and Heart Failure · Not applicable, Interventional, and Other
The study is designed to characterize the acute safety and performance of the EV ICD System for Japanese patients.
623 studies on the registry are indexed under Tachycardia; 81 are open to participants now.
This study's enrollment of 14 is below the median of 64 across 379 interventional studies indexed under Tachycardia.
Browse Tachycardia studies →Medtronic Cardiac Rhythm and Heart Failure is the lead sponsor of 239 studies on the registry; 6 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 17 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patient is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up.
[i] Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Hlatky MA, Granger CB, Hammill SC, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias. [ii] Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliot PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal 2015 36:41 (2793-2867). https://doi.org/10.1093/eurheartj/ehv316
Exclusion Criteria:
Patients with these medical interventions are excluded from participation in the study:
Or any other prior/planned medical intervention not listed that precludes their participation in the opinion of the Investigator.
Patient has previous pericarditis that:
Patients with these medical conditions or anatomies are excluded from participation in the study:
Patients with a medical condition that precludes them from undergoing defibrillation testing:
[iii] 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing). [iv] ACC/AHA/HRS guidelines for Cardiac Resynchronization Therapy. [v] As documented on echo or MRI. [vi] As documented on CT scan or MRI.
Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.
Device: Defibrillation using the Extravascular ICD
VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
Safety Outcome - Freedom From Major Complications Related to the EV ICD System and/or Procedure at 2 Weeks Post-implant
The endpoint is defined as a subject's first occurrence of a major complication related to the EV ICD System and/or procedure, as determined by an independent Clinical Events Committee (CEC), that occurs on or prior to 2 weeks (14 days) post-implant.
Time frame: 2 weeks (14 days) post-implant
Efficacy Outcome - Defibrillation Efficacy at Implant of the EV ICD System
Each subject will demonstrate a successful defibrillation outcome if either 2 successive induced ventricular fibrillation episodes are terminated by the subject's device delivering a shock at the required energy level, or if one such episode is successfully terminated by the subject's device delivering a shock at a lower energy level. Up to 6 such episodes may be induced to test device efficacy.
Time frame: At Implant
The first site was activated on 20JAN2023. The first EV ICD Japan subject was enrolled on 22FEB2023 and implanted on 01 MAR 2023. The last subject enrollment occurred on 27SEP2023, and the last implant occurred on 03OCT2023. Sites were notified of enrollment completion on 01DEC2023.
| Milestone | Implant Attempt |
|---|---|
| Started | 14 |
| Completed | 14 |
| Not completed | 0 |
The endpoint is defined as a subject's first occurrence of a major complication related to the EV ICD System and/or procedure, as determined by an independent Clinical Events Committee (CEC), that occurs on or prior to 2 weeks (14 days) post-implant.
| Participants | Implant Attempt |
|---|---|
| Safety Outcome - Freedom From Major Complications Related to the EV ICD System and/or Procedure at 2 Weeks Post-implant | 13 |
Each subject will demonstrate a successful defibrillation outcome if either 2 successive induced ventricular fibrillation episodes are terminated by the subject's device delivering a shock at the required energy level, or if one such episode is successfully terminated by the subject's device delivering a shock at a lower energy level. Up to 6 such episodes may be induced to test device efficacy.
| Participants | Implant Attempt |
|---|---|
| Efficacy Outcome - Defibrillation Efficacy at Implant of the EV ICD System | 14 |
Collected over Among the 14 enrolled subjects, the average follow-up duration from enrollment to last documented contact was 112.9 ± 59.9 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enrolled Japan Study | 0/14 (0%) | 5/14 (35.7%) | 10/14 (71.4%) |
| Event | Enrolled Japan Study |
|---|---|
| Incision site painInjury, poisoning and procedural complications | 3/14 |
| Cardiac perforationCardiac disorders | 1/14 |
| Device inversionProduct Issues | 1/14 |
| Procedural painInjury, poisoning and procedural complications | 1/14 |
| Event | Enrolled Japan Study |
|---|---|
| Incision site painInjury, poisoning and procedural complications | 3/14 |
| InflammationGeneral disorders | 2/14 |
| Sputum retentionRespiratory, thoracic and mediastinal disorders | 2/14 |
| InsomniaPsychiatric disorders | 1/14 |
| Ventricular tachycardiaCardiac disorders | 1/14 |
| Chronic gastritisGastrointestinal disorders | 1/14 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/14 |
| Hiatus herniaGastrointestinal disorders | 1/14 |
| Medical device site painGeneral disorders | 1/14 |
| Coronavirus infectionInfections and infestations | 1/14 |
Subjects who underwent an implant attempt of the Extravascular ICD System
| Age, Continuous(years) | Implant Attempt EV ICD Japan |
|---|---|
| Mean | 53.6 ± 14.7 |
| Sex: Female, Male(Participants) | Implant Attempt EV ICD Japan |
|---|---|
| Female | 2 |
| Male | 12 |
| Ethnicity (NIH/OMB)(Participants) | Implant Attempt EV ICD Japan |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 0 |
| Unknown or Not Reported | 14 |
| Race (NIH/OMB)(Participants) | Implant Attempt EV ICD Japan |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 14 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medtronic Cardiac Rhythm and Heart Failure